Quest Diagnostics and NewYork-Presbyterian, or NYP, announced a strategic agreement designed to broaden access to quality, innovative laboratory services for the providers and patients of NewYork-Presbyterian primarily in New York as well as the Tri-State Area and beyond. Under a definitive agreement, Quest will acquire select assets of the laboratory services business of NewYork-Presbyterian. NewYork-Presbyterian will still own and operate world-renowned hospital labs, including its anatomic pathology services, to continue providing high quality, complex clinical laboratory services with its academic partners. The parties expect to complete the transaction in the second quarter of 2023, pending customary regulatory approvals. Financial details of the transaction were not disclosed.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DGX:
- Quest Diagnostics and NewYork-Presbyterian Agree to Laboratory Services Transaction
- Quest Diagnostics raises quarterly dividend, increases share repurchase program
- Quest Diagnostics sees FY23 adjusted EPS $8.40-$9.00, consensus $8.69
- Quest Diagnostics reports Q4 adjusted EPS $1.98, consensus $1.91
- QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS; PROVIDES GUIDANCE FOR FULL YEAR 2023